MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
4568

4568.T

Daiichi Sankyo Company, Limited

$2751
15.5
 (0.57%)
Exchange:  JPX
Market Cap:  5.006T
Shares Outstanding:  1.939B
Delayed data
Calculate 4568.T Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Drug Manufacturers – General
   
CEO:  Hiroyuki Okuzawa
Full Time Employees:  20171
Address: 
Daiichi Sankyo Building A/B
Tokyo
TY
103-8426
JP
Website:  https://www.daiichisankyo.com
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer’s disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202420252026
Revenue1,601,688,0001,886,256,0002,123,045,000
Gross Profit1,186,366,0001,470,459,0001,454,000,000
EBITDA271,129,000380,573,000348,878,000
Operating Income184,200,000303,293,000207,312,000
Net Income200,731,000295,756,000259,874,000

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202420252026
Total Assets3,461,135,0003,456,119,0004,005,390,000
Total Liabilities1,772,533,0001,832,703,0002,341,207,000
Total Stockholders Equity1,688,173,0001,623,416,0001,664,179,000
Total Debt156,002,000155,891,000300,481,000
Cash and Cash Equivalents415,264,000367,456,000449,807,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202420252026
Operating Cash Flow599,258,00053,842,00077,655,000
Capital Expenditure-88,321,000-116,259,000-128,365,000
Free Cash Flow510,937,000-62,417,000-50,710,000
Net Income200,731,000295,756,000259,874,000
Net Change in Cash80,439,000-47,808,00082,351,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2031Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)3,025,557,318.258Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)3,545,405,747.053Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)3,204,581,600Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)666,484,341.832Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)786,468,068.636Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)707,804,073.168Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)468,113,296.075Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)574,562,930.032Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)504,772,186.352Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)1,128,268,346.782Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)1,322,126,358.923Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)1,195,028,751.279Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)272.660Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)310.360Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)252.860Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)11Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)12Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
2.29
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
21.15
?Enterprise Value
 (TTM)
: 
4.947T  ?EV/FCF
 (TTM)
: 
-2125.8
?Dividend Yield
 (TTM)
: 
2.79%  ?Payout Ratio
 (TTM)
: 
59.07%
?ROE
 (TTM)
: 
14.44%  ?ROIC
 (TTM)
: 
5.72%
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.29
?P/B
 (TTM)
: 
2.99  ?Current Ratio
 (TTM)
: 
2.92

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
2,543.06Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about 4568.T valuation

Is Daiichi Sankyo Company, Limited (4568.T) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Daiichi Sankyo Company, Limited (4568.T) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is 4568.T a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether 4568.T trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is 4568.T’s P/E ratio?

You can see 4568.T’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for 4568.T?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is 4568.T a good long-term investment?

Whether 4568.T fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

4568.T

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.57
MARKETSnap

Trading Metrics:

Open: 2730   Previous Close: 2735.5
Day Low: 2726   Day High: 2770
Year Low: 2390   Year High: 4178
Price Avg 50: 2747.85   Price Avg 200: 2914.95
Volume: 4.918M   Average Volume: 7.676M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read